Q BioMed Announces Strategic Partnership with SRI International for Formulation and Preclinical Development of QBM-001 for Pediatric Nonverbal Disorder in Autistic Children

Collaboration with SRI Provides QBioMed Expertise in Formulation Development and Preclinical Work in Autism, as well as CMC and Manufacturing capability NEW YORK, December 12, 2018 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce a collaborative agreement with SRI International to provide formulation development, preclinical development, and early clinical manufacturing of QBM-001, in support…

Read More